Optimal assessment of baseline treadmill walking performance in claudication clinical trials

Vascular Medicine

Volumn 12, Issue 2, 2007, Pages 97-104

  Brass, Eric P ^a   Jiao, Jenny ^b   Hiatt, William ^c  

^a HARBOR UCLA MEDICAL CENTER   (United States)

^b Catalyst Pharmaceutical Research   (United States)

^c UNIVERSITY OF COLORADO   (United States)

Author keywords

Claudication; Clinical trials; Exercise testing; Peripheral arterial disease

Indexed keywords

NM 702; PHOSPHODIESTERASE INHIBITOR; PLACEBO; UNCLASSIFIED DRUG;

ARTERY DISEASE; ARTICLE; CLAUDICATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FOLLOW UP; HEART PERFORMANCE; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL; REPRODUCIBILITY; TREADMILL EXERCISE; TREATMENT RESPONSE; WALKING;

EXERCISE TEST; HUMANS; INTERMITTENT CLAUDICATION; LEG; PHOSPHODIESTERASE INHIBITORS; PYRIDAZINES; RANDOMIZED CONTROLLED TRIALS; REPRODUCIBILITY OF RESULTS; WALKING;

EID: 34347207229     PISSN: 1358863X     EISSN: None     Source Type: Journal    
DOI: 10.1177/1358863X07078602     Document Type: Article

References (10)

1. Hiatt WR. Medical treatment of peripheral arterial disease and claudication. N Engl J Med 2001; 344: 1608-21.
2. McDermott MM, Mehta S, Liu K et al. Leg symptoms, the ankle-brachial index, and walking ability in patients with peripheral arterial disease. J Gen Intern Med 1999; 14: 173-81.
3. Hiatt WR, Hirsch AT, Regensteiner JG, Brass EP. Clinical trials for claudication. Assessment of exercise performance, functional status, and clinical end points. Circulation 1995; 92: 614-21.
4. Hiatt WR, Cox L, Greenwalt M, Griffin A, Schechter C. Quality of the assessment of primary and secondary endpoints in claudication and critical leg ischemia trials. Vasc Med 2005; 10: 207-13.
5. McDermott MM, Liu K, Greenland P et al. Functional decline in peripheral arterial disease: associations with the ankle brachial index and leg symptoms. JAMA 2004; 292: 453-61.
6. Imparato AM, Kim GE, Davidson T, Crowley JG. Intermittent claudication: its natural course. Surgery 1975; 78: 795-99.
7. Brass EP, Anthony R, Cobb FR, Koda I, Jiao J, Hiatt WR. The novel phosphodiesterase inhibitor NM-702 improves claudication-limited exercise performance in patients with peripheral arterial disease. J Am Coll Cardiol 2006; 48: 2539-45.
8. Gardner AW, Skinner JS, Cantwell BW, Smith LK. Progressive vs single-stage treadmill tests for evaluation of claudication. Med Sci Sports Exerc 1991; 23: 402-08.
9. Cohen J. Statistical power analysis for the behavioral sciences. Hillsdale, NJ: Lawrence Erlbaum Associates; 1988.
10. Brevetti G, Diehm C, Lambert D. European multicenter study on propionyl-L-carnitine in intermittent claudication. J Am Coll Cardiol 1999; 34: 1618-24.